Dropout rates did not differ between antidepressants .
The latter study showed very promising results of  sertraline  in children and adolescents with GAD , which warrants its replication in larger sample s. REVIEW ER 'S CONCLUSIONS The available evidence suggests that antidepressants are superior to placebo in treating GAD .
There is also evidence from placebo-controlled trials suggesting that these drugs are well tolerated by GAD patients .
Further trials of antidepressants for GAD will help to demonstrate which antidepressants should be used for which patients
BACKGROUND Pharmacological treatments have been successfully used to treat  Generalized Anxiety Disorder ( GAD ) .
The mainstay for the pharmacological treatment of GAD in past decades has been the use of benzodiazepine and non benzodiazepine anxiolytics .
Data emerging over the last two decades have shown that antidepressants may be equally effective to anxiolytics for treating GAD .
The use of antidepressants for treating GAD may be advantageous , due to the fact that GAD presents a high co morbidity ratio with major depressive disorder ( 62 % ) and dysthymia ( 37 % ) .
OBJECTIVES To assess the efficacy and acceptability of antidepressants for treating generalized anxiety disorder .
Phenomenology and course of generalised anxiety disorder.
BACKGROUND The diagnostic category of generalised anxiety disorder ( GAD ) was originally intended to describe residual anxiety states . Over the years clinical criteria have been refined in an attempt to describe a unique diagnostic entity . Given these changes , little is known about the clinical course of this newly defined disorder . This study investigates the longitudinal course , including remission and relapse rates , for patients with DSM-III-R defined GAD . METHOD Analysis of the 164 patients with GAD participating in the Harvard Anxiety Research Program . Patients were assessed with a structured clinical interview at intake and re-examined at six month intervals for two years and then annually for one to two years .  Psychiatric Status Ratings were assigned at each interview point . Kaplan-Meier curves were constructed to assess likelihood of remission . RESULTS Comorbidity was high , with panic disorder and social phobia as the most frequently found comorbid disorders . The likelihood of remission was 0.15 after one year and 0.25 after two years . The probability of becoming asymptomatic from all psychiatric symptoms was only 0.08 . CONCLUSIONS This prospect i ve study confirms the chronicity associated with GAD and extends this finding to define the one and two year remission rates for the disorder . Likelihood of remission for GAD and any other comorbid condition after one year was half the annual remission rate for GAD alone
Dropout rates did not differ between antidepressants .
The latter study showed very promising results of  sertraline  in children and adolescents with GAD , which warrants its replication in larger sample s. REVIEW ER 'S CONCLUSIONS The available evidence suggests that antidepressants are superior to placebo in treating GAD .
There is also evidence from placebo-controlled trials suggesting that these drugs are well tolerated by GAD patients .
Further trials of antidepressants for GAD will help to demonstrate which antidepressants should be used for which patients
BACKGROUND Pharmacological treatments have been successfully used to treat  Generalized Anxiety Disorder ( GAD ) .
The mainstay for the pharmacological treatment of GAD in past decades has been the use of benzodiazepine and non benzodiazepine anxiolytics .
Data emerging over the last two decades have shown that antidepressants may be equally effective to anxiolytics for treating GAD .
The use of antidepressants for treating GAD may be advantageous , due to the fact that GAD presents a high co morbidity ratio with major depressive disorder ( 62 % ) and dysthymia ( 37 % ) .
OBJECTIVES To assess the efficacy and acceptability of antidepressants for treating generalized anxiety disorder .